Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 6, Issue 7

comparison of viral replication and cytopathology induced by SARS-CoV-2 variants Open Access

Abstract

A myriad of coronaviruses cause diseases from a common cold to severe lung infections and pneumonia. SARS-CoV-2 was discovered to be the etiologic agent of the Coronavirus pandemic and many laboratory techniques were examined for virus culture and basic and applied research. Understanding the replication kinetics and characterizing the effect the virus has on different cell lines is crucial for developing studies. With the emergence of multiple variants of SARS-CoV-2, a comparison between their infectivity and replication in common cell lines will help give us a clear understanding of their characteristic differences in pathogenicity. In this study we compared the cytopathic effect and replication of Wild-Type (USA/WA1), Omicron (B.1.1.529), and Delta (B.1.617.2) variants on five different cell lines; VeroE6, VeroE6 cells expressing high endogenous ACE2, VeroE6 cells expressing human ACE2 and TMPRSS2, Calu3 cells highly expressing human ACE2 and A549 cells. This data will aid researchers with experimental planning and viral pathogenicity analysis and provide a baseline for testing any future variants.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): A549 , BSL3 , Calu3 , cytopathic effect (CPE) , SARS-CoV-2 , vero E6 and viral replication
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000716.v3
2024-07-22
2026-03-09

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/acmi/6/7/acmi000716.v3.html?itemId=/content/journal/acmi/10.1099/acmi.0.000716.v3&mimeType=html&fmt=ahah

References

  1. Phadke KS, Higdon N, Bellaire BH. In vitro comparison of SARS-CoV-2 variants. Figshare 2023 [View Article]
     [Google Scholar]
  2. ICVT Virus taxonomy: ninth report of the International Committee on taxonomy of viruses Part II-the positive sense single stranded RNA viruses; 2012 p 806
  3. Zhu N, Zhang D, Wang W, Li X, Yang B et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–733 [View Article] [PubMed]
     [Google Scholar]
  4. World Health Organization WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020; 2020 https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 accessed 6 January 2023
  5. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20:533–534 [View Article] [PubMed]
     [Google Scholar]
  6. Li Q, Guan X, Wu P, Wang X, Zhou L et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382:1199–1207 [View Article]
     [Google Scholar]
  7. Wang D, Hu B, Hu C, Zhu F, Liu X et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061–1069 [View Article] [PubMed]
     [Google Scholar]
  8. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD et al. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect 2016; 92:235–250 [View Article] [PubMed]
     [Google Scholar]
  9. Centers for Disease Control and Prevention SARS-CoV-2 variant classifications and definitions; 2023 https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html accessed 6 January 2023
  10. Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS et al. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun 2021; 124:102715 [View Article]
     [Google Scholar]
  11. Earnest R, Uddin R, Matluk N, Renzette N, Turbett SE et al. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Cell Rep Med 2022; 3:100583 [View Article] [PubMed]
     [Google Scholar]
  12. Poudel S, Ishak A, Perez-Fernandez J, Garcia E, León-Figueroa DA et al. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts - What is known so far?. Travel Med Infect Dis 2022; 45:102234 [View Article] [PubMed]
     [Google Scholar]
  13. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:271–280 [View Article] [PubMed]
     [Google Scholar]
  14. Ren X, Glende J, Al-Falah M, de Vries V, Schwegmann-Wessels C et al. Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J Gen Virol 2006; 87:1691–1695 [View Article] [PubMed]
     [Google Scholar]
  15. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020; 117:7001–7003 [View Article] [PubMed]
     [Google Scholar]
  16. Hierholzer JC, Killington RA. Virology Methods Manual Academic Press; 1996 p 374
     [Google Scholar]
  17. Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol 1968; 2:955–961 [View Article] [PubMed]
     [Google Scholar]
  18. Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J Gen Virol 2020; 101:925–940 [View Article] [PubMed]
     [Google Scholar]
  19. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270–273 [View Article] [PubMed]
     [Google Scholar]
  20. Ghosh S, Dellibovi-Ragheb TA, Kerviel A, Pak E, Qiu Q et al. β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 2020; 183:1520–1535 [View Article] [PubMed]
     [Google Scholar]
  21. Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D et al. Syncytia formation by SARS‐CoV‐2‐infected cells. EMBO J 2020; 39: [View Article]
     [Google Scholar]
  22. Rajah MM, Bernier A, Buchrieser J, Schwartz O. The mechanism and consequences of SARS-CoV-2 spike-mediated fusion and syncytia formation. J Mol Biol 2022; 434:167280 [View Article] [PubMed]
     [Google Scholar]
  23. Li S, Zhang Y, Guan Z, Li H, Ye M et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther 2020; 5:235 [View Article] [PubMed]
     [Google Scholar]
  24. Shuai H, Chan JF-W, Hu B, Chai Y, Yuen TT-T et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 2022; 603:693–699 [View Article]
     [Google Scholar]
  25. Zhao H, Lu L, Peng Z, Chen L-L, Meng X et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect 2022; 11:277–283 [View Article]
     [Google Scholar]
  26. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2022; 602:30 [View Article]
     [Google Scholar]
  27. Kim S, Liu Y, Ziarnik M, Seo S, Cao Y et al. Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern. J Comput Chem 2023; 44:594–601 [View Article] [PubMed]
     [Google Scholar]
  28. Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 2022; 603:706–714 [View Article] [PubMed]
     [Google Scholar]
  29. Monteil V, Stephanie D, Klingström J, Thålin C, Kellner MJ et al. Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections. bioRxiv 2021DOI: 10.1101/2021.12.25.474113 [Preprint]
     [Google Scholar]
  30. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 2022; 603:700–705 [View Article] [PubMed]
     [Google Scholar]
  31. Hui KPY, Ho JCW, Cheung M-C, Ng K-C, Ching RHH et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 2022; 603:715–720 [View Article] [PubMed]
     [Google Scholar]
  32. Chu H, Chan JF-W, Yuen TT-T, Shuai H, Yuan S et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe 2020; 1:e14–e23 [View Article] [PubMed]
     [Google Scholar]
  33. Khatri R, Siddqui G, Sadhu S, Maithil V, Vishwakarma P et al. Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. Med Microbiol Immunol 2022; 212:103–122 [View Article] [PubMed]
     [Google Scholar]
  34. Sagar S, Rathinavel AK, Lutz WE, Struble LR, Khurana S et al. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. Clin Transl Med 2021; 11:e281 [View Article] [PubMed]
     [Google Scholar]
  35. Chang CW, Parsi KM, Somasundaran M, Vanderleeden E, Liu P et al. A newly engineered A549 cell line expressing ACE2 and TMPRSS2 is highly permissive to SARS-CoV-2, including the Delta and Omicron variants. Viruses 2022; 14:1369 [View Article] [PubMed]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000716.v3
Loading
In vitro comparison of viral replication and cytopathology induced by SARS-CoV-2 variants
Access Microbiology 6, 000716.v3 (2024); https://doi.org/10.1099/acmi.0.000716.v3
/content/journal/acmi/10.1099/acmi.0.000716.v3
/content/journal/acmi/10.1099/acmi.0.000716.v3
Loading

Data & Media loading...

Supplements

Loading data from figshare Loading data from figshare

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error